Nkarta, Inc. (NKTX) Income Statement

The reported figures show zero revenue in the majority of quarters, leaving the revenue growth rate largely undefined and the reported percentage swings in the data without a revenue denominator to anchor them. This pattern suggests the company's income statement is driven by research and development spending rather than commercial sales, which is typical of clinical-stage biotechnology. Investors should monitor for any future licensing or collaboration revenue, as the current data does not support an assessment of revenue durability.

R&D consumed the large majority of operating expenses in every period, with the most recent quarter showing $29.0M in R&D against $14.1M in SG&A. The jump in SG&A in 2026Q2 relative to the prior quarters may warrant further investigation, as it could reflect a change in corporate activity, though the data alone does not establish the cause. The consistent R&D base implies a sustained clinical development program whose pace of spending will largely determine cash consumption.

The negative gross profit values arise from recorded cost of goods sold without corresponding revenue, which appears to reflect pre-commercial production or service costs rather than a margin structure. Because no revenue denominator exists, gross margin and pricing power relative to peers cannot be meaningfully assessed. Investors should treat the margin fields as data unavailable rather than as evidence of structural profitability.